CompanyGraph
What stands out
- Returns appear driven by leverage
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $12.93B, above the global median of $1.18B
- PositionOperating margin is 59.8%, higher than 95% of its Biotechnology peers (median 11.9%)
- Interpretations13 currently firing — 13
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Returns appear driven by leverage
Financials view
Market Capitalization
12.93BUSDvs all stocks (USD)
Trailing P/E
33.40xvs Biotechnology peers
Revenue (TTM)
1.66BUSDvs all stocks (USD)
Profit Margin
24.86%vs Biotechnology peers
Beta
0.8820xvs all stocks
52-Week Change
55.41%vs all stocks
Market Capitalization
12.93BUSDvs all stocks (USD)
Enterprise Value
14.87BUSDvs all stocks (USD)
Trailing P/E
33.40xvs Biotechnology peers
Forward P/E
10.96xvs Biotechnology peers
PEG Ratio
0.7571xvs Biotechnology peers
Price to Sales (TTM)
7.77xvs Biotechnology peers
Price to Book (MRQ)
90.47xvs Biotechnology peers
Enterprise to Revenue
8.94xvs Biotechnology peers
Enterprise to EBITDA
14.16xvs Biotechnology peers
Gross Margin
83.54%vs Biotechnology peers
Profit Margin
24.86%vs Biotechnology peers
Operating Margin
59.80%vs Biotechnology peers
Return on Assets (TTM)
25.49%vs Biotechnology peers
Return on Equity (TTM)
173.67%vs Biotechnology peers
Revenue (TTM)
1.66BUSDvs all stocks (USD)
Revenue per Share (TTM)
14.15USDUpdated Sep 27, 2026Quarterly Revenue Growth
47.70%vs Biotechnology peers
Gross Profit (TTM)
1.27BUSDvs all stocks (USD)
EBITDA (TTM)
1.05BUSDvs all stocks (USD)
Net Income (TTM)
413.60MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
39.20%vs Biotechnology peers
Operating Cash Flow (TTM)
818.60MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
337.31MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
1.40BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
228.77MUSDFY2025 · Dec 31, 2025Operating Income
802.59MUSDvs all stocks (USD)
Pre-tax Income
466.88MUSDFY2025 · Dec 31, 2025Income Tax Expense
149.99MUSDFY2025 · Dec 31, 2025Net Income
316.89MUSDFY2025 · Dec 31, 2025EBIT
485.00MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
890.64MUSDFY2025 · Dec 31, 2025Research & Development
81.49MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
207.09MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
18.13MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.64USDFY2025 · Dec 31, 2025EPS (Diluted)
2.56USDFY2025 · Dec 31, 2025Basic Shares Outstanding
119.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
119.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
316.89MUSDFY2025 · Dec 31, 2025Operating Cash Flow
630.45MUSDFY2025 · Dec 31, 2025Free Cash Flow
623.48MUSDDerived from operating cash flow minus capital expenditure. This filing charges 88.05M of depreciation against 6.97M of capital expenditure, and its own free-cash-flow line reads 356.82M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
136.42MUSDFY2025 · Dec 31, 2025Income Tax Paid
134.64MUSDFY2025 · Dec 31, 2025Interest Paid
11.43MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
316.89MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
88.05MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
634.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
51.56MUSDFY2025 · Dec 31, 2025Other Non-cash Items
298.82MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-128.06MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
2.55MUSDFY2025 · Dec 31, 2025Capital Expenditures
-6.97MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-287.77MUSDFY2025 · Dec 31, 2025Net Acquisitions
-725.97MUSDFY2025 · Dec 31, 2025Purchase of Investments
-247.35MUSDFY2025 · Dec 31, 2025Sale of Investments
722.25MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-258.04MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
1.47BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.02BUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-342.37MUSDFY2025 · Dec 31, 2025Other Financing Charges
-215.76MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-107.00MUSDFY2025 · Dec 31, 2025Shares Outstanding
114.04MSharesUpdated Sep 27, 2026Float Shares
112.19MSharesUpdated Sep 27, 2026Shares Short
15.15MSharesUpdated Sep 27, 2026Short Ratio
9.83daysvs all stocks
Short % of Shares Outstanding
17.50%vs all stocks
% Held by Insiders
1.11%vs all stocks
% Held by Institutions
112.14%vs all stocks
Total Cash (MRQ)
231.00MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.04USDUpdated Sep 27, 2026Total Debt (MRQ)
2.18BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
15.18xvs Biotechnology peers
Current Ratio (MRQ)
2.71xvs Biotechnology peers
Book Value per Share (MRQ)
1.26USDUpdated Sep 27, 2026Total Assets
2.53BUSDvs all stocks (USD)
Total Current Assets
825.21MUSDFY2025 · Dec 31, 2025Total Liabilities
2.48BUSDFY2025 · Dec 31, 2025Total Non-current Assets
1.70BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.30BUSDFY2025 · Dec 31, 2025Total Current Liabilities
177.09MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
133.82MUSDFY2025 · Dec 31, 2025Other Short-term Investments
9.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
434.27MUSDFY2025 · Dec 31, 2025Inventory
176.47MUSDFY2025 · Dec 31, 2025Accounts Payable
20.90MUSDFY2025 · Dec 31, 2025Long-term Debt
2.14BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
113.86MUSDFY2025 · Dec 31, 2025Common Stock (Book)
118.00KUSDFY2025 · Dec 31, 2025Retained Earnings
54.79MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
48.81MUSDvs all stocks (USD)
52-Week Low
61.23USDUpdated Sep 27, 202652-Week High
116.85USDUpdated Sep 27, 202652-Week Change
55.41%vs all stocks
Beta
0.8820xvs all stocks
50-Day MA
99.74USDUpdated Sep 27, 2026200-Day MA
77.13USDUpdated Sep 27, 2026Avg 10-Day Volume
3.07MSharesUpdated Sep 27, 2026Avg 30-Day Volume
2.09MSharesUpdated Sep 27, 2026Diluted EPS (TTM)
3.41USDUpdated Sep 27, 2026Other Income / Expense
-317.59MUSDFY2025 · Dec 31, 202513 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
How does this company use capital?
Diagnostic
Elevated ROE With High Debt-to-Equity and Equity Multiplier
Return on equity reads high on a balance sheet carrying a lot of debt against that equity.
Reads
Cash-Backed Growth Configuration
Revenue has grown steadily, and the cash arriving matches reported profit.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
High ROE Relative To Gross Margin
Its return on equity is high for the gross margin it earns, with revenue up three years and profit in all five.
Reads
Operating Income Growing With Multi-Year Revenue Growth
Revenue up in each of five years, with operating income up in each of four.
Reads
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 59.8%, higher than 95% of its Biotechnology peers (median 11.9%)Significant
Operating margin: 0.60Industry median: 0.12Industry P95: 0.57Peers compared: 24.00
Return on equity is 173.7%, higher than 95% of its Biotechnology peers (median 6.3%)Significant
Return on equity: 1.74Industry median: 0.06Industry P95: 0.40Peers compared: 24.00
Return on assets is 25.5%, higher than 95% of its Biotechnology peers (median 3.6%)Significant
Return on assets: 0.25Industry median: 0.04Industry P95: 0.18Peers compared: 24.00
Debt-to-equity is 15.18×, higher than 95% of its Biotechnology peers (median 0.24×)Significant
Debt-to-equity: 15.18Industry median: 0.24Industry P95: 4.09Peers compared: 24.00
Price-to-book is 90.47×, higher than 95% of its Biotechnology peers (median 9.91×)Significant
Price-to-book: 90.47Industry median: 9.91Industry P95: 33.49Peers compared: 24.00
Structural Tensions
Returns appear driven by leverageSignificant
Return on Equity: 1.74Debt-to-Equity: 15.18
Financial Health
Altman Z-Score 4.66: safe zoneNotable
Altman Z-Score: 4.66
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $12.93B, above the global median of $1.18BNotable
Market cap (USD): 12,927,422,200Global Median: 1,180,223,658.953
Revenue is $1.66B, above the global median of $548.88MNotable
Revenue (USD): 1,663,737,984Global Median: 548,883,780.48
Levered free cash flow is $337.31M, above the global median of $18.73MNotable
Levered free cash flow (USD): 337,308,640Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
BridgeBio Pharma, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ALTEOGEN Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai United Imaging Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Penumbra Inc.
Tier 1ProductionApproval-Gated PipelineRule
Corcept Therapeutics Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Summit Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Yunnan Baiyao Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Swedish Orphan Biovitrum AB
Tier 1ProductionApproval-Gated PipelineRuleRisk
Zhejiang NHU Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Madrigal Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Medpace Holdings Inc.
8 interpretationsCash-Backed Growth ConfigurationCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthHigh ROE Relative To Gross Margin
NVIDIA Corporation
8 interpretationsCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingOperating Income Growing With Multi-Year Revenue GrowthRevenue Growth With Elevated MarginHigh ROE Relative To Gross Margin
Groupe Dynamite Inc.
8 interpretationsCash-Backed Growth ConfigurationCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedElevated ROE With High Debt-to-Equity and Equity MultiplierOperating Income Growing With Multi-Year Revenue GrowthHigh ROE Relative To Gross Margin